Upon completion of the video presentation, to finish the activity and claim your credit, please click here.

Supported by an educational grant from Puma Biotechnology.

Advances in Extended Adjuvant HER2-Positive Early Breast Cancer

G. Thomas Budd, MD
Taussig Cancer Center at Cleveland Clinic

Wendy H. Vogel, MSN. FNP, AOCNP®
Wellmont Cancer Institute

Examine the mechanisms of action of extended adjuvant therapies for HER2-positive early breast cancer, in addition to strategies for combating patients’ side effects and the latest guidelines on HER2 testing. Advanced practitioners can also learn about their critical role in properly selecting patients for treatment, educating them about their treatment options, and managing treatment adherence.



 

Download Podcast

   To claim credit for podcast click here
 
 

Download Transcript

 
 

Download Slides

 
 

Download Slides & Transcripts

   To claim credit for the slides & transcript click here





These CME/CE/CPE accredited activities are jointly provided by

JADPRO CE Logo Harborside Press Logo APSHO Logo Annenberg Logo
Copyright © 2010-2018 Harborside Press, LLC All rights reserved.                Home | Current Issue | Previous Issue | Submissions | About JADPRO | Advertising | Privacy Policy | Contact
Copyright Notice/Disclaimer
Bot trap - Don't go here